Valore202020212022202320242025TTMSpese di vendita, generali e amministrative7.66 B7.69 B7.81 B7.77 B8.41 B7.27 B7.3 BRicerca e sviluppo11.14 B11.35 B9.51 B9.3 B11.16 B9.95 B10.34 BReddito operativo-18.64 B8.1 B7.71 B8.44 B-8.38 B9.33 B9.6 BProventi non operativi, Totale3.7 B1.9 B-1.8 B1.29 B-517 M471 M1.18 BOneri finanziari, al netto degli interessi capitalizzati1.42 B1.33 B1.23 B1.17 B1.95 B1.89 B1.81 BProventi non operativi, esclusi gli oneri finanziari-33 M-154 M-2.45 B-1.04 B-1.57 B-746 M-258 MEntrate/uscite straordinarie2.31 B720 M-576 M1.16 B-893 M-674 M-367 MUtile al lordo delle imposte-6.87 B8.1 B7.71 B8.44 B-8.38 B9.33 B9.6 BQuota di utile—231 M-108 M-38 M44 M47 M81 MImposte2.12 B1.08 B1.37 B400 M554 M2.27 B2.32 BInteressi di minoranza20 M20 M18 M————Altri proventi/oneri al netto delle imposte177 M-142 M-232 M-308 M-94 M-232 M-248 MUtile netto al lordo delle attività cessate-9.02 B6.99 B6.33 B8.03 B-8.95 B7.05 B7.28 BAttività cessate———————Utile netto-9.02 B6.99 B6.33 B8.03 B-8.95 B7.05 B7.28 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-9.02 B6.99 B6.33 B8.03 B-8.95 B7.05 B7.28 BUtile base per azione (EPS base)-3.993.152.973.88-4.413.473.57Utile diluito per azione (EPS diluito)-3.993.122.953.86-4.413.463.57Numero medio di azioni ordinarie in circolazione2.26 B2.22 B2.13 B2.07 B2.03 B2.03 B—Azioni diluite in circolazione2.26 B2.25 B2.15 B2.08 B2.03 B2.04 B—EBITDA3.51 B18.78 B17.99 B18.2 B1.22 B13.34 B13.19 BEBIT-6.87 B8.1 B7.71 B8.44 B-8.38 B9.33 B9.6 BCosto del fatturato11.77 B9.94 B10.14 B10.69 B13.97 B13.94 B14.32 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)10.38 B10.69 B10.28 B9.76 B9.6 B4.01 B3.59 B
Bristol-Myers Squibb Company Common Stock
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.